Don't forget this:

Cellceutix's Kevetrin now has dual matriculation at Harvard's Beth Israel. This is an eyebrow-raising feat. How often does any small company like Kevetrin's parent qualify to place a pharmaceutical compound in a Harvard clinical? Kevetrin has two! (Seeking Alpha 8/2012)